SLC5A2 and diabetic kidney disease: Herein, we aimed to assess the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with diabetic kidney disease.<h4>Methods</h4>PubMed, Embase, and Web of Science databases were searched for eligible randomized clinical trials (RCTs) published up to July 2024.